Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 30 2021 - 4:32PM
eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development
of selective translation regulator inhibitors (STRIs) for the
treatment of cancer, today announced that eFFECTOR-supported
research from Baylor College of Medicine entitled, “The RNA
helicase EIF4A is a therapeutic vulnerability in triple-negative
breast cancer” has been accepted as a poster presentation at the
upcoming 2021 AACR-NCI-EORTC International Conference on Molecular
Targets and Cancer Therapeutics.
Presentation details:
Title: The RNA helicase EIF4A is a therapeutic
vulnerability in triple-negative breast cancer
Author: Na Zhao, Ph.D., Postdoctoral Associate,
Dr. Jeffrey M. Rosen Lab, Department of Molecular & Cellular
Biology, Dan L Duncan Comprehensive Cancer Center, Baylor College
of Medicine
Presentation Date and Time: Recorded
presentation to be available on October 7 at 9 a.m. ET – October 10
at 5:45 pm ET
Abstract Number: 0630
Hosted by the European Organization for Research
and Treatment of Cancer (EORTC), the National Cancer Institute
(NCI) and the American Association for Cancer Research (AACR), the
2021 Molecular Targets and Cancer Therapeutics conference will take
place as a virtual event October 7-10, 2021. The Symposium
brings together academics, scientists and pharmaceutical industry
representatives from across the globe to learn the latest
innovations in drug development, target selection, and the impact
of new discoveries in molecular biology. Additional meeting
information is available on AACR’s website.
About eFFECTOR Therapeutics
eFFECTOR is a clinical-stage biopharmaceutical company focused
on pioneering the development of a new class of oncology drugs
referred to as STRIs. eFFECTOR’s STRI product candidates target the
eIF4F complex and its activating kinase, mitogen-activated protein
kinase interacting kinase (MNK). The eIF4F complex is a central
node where two of the most frequently mutated signaling pathways in
cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the
translation of select mRNA into proteins that are frequent culprits
in key disease-driving processes. Each of eFFECTOR’s product
candidates is designed to act on a single protein that drives the
expression of multiple functionally related proteins, including
oncoproteins and immunosuppressive proteins in T cells, that
together control tumor growth, survival and immune evasion.
eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor
currently being evaluated in KICKSTART, a randomized, double-blind,
placebo-controlled Phase 2b trial of tomivosertib in combination
with pembrolizumab in patients with metastatic non-small cell lung
cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is
currently being evaluated in Phase 2a expansion cohorts in certain
biomarker-positive solid tumors, including ER+ breast cancer and
KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer
to develop inhibitors of a third target, eIF4E. In addition to the
company’s oncology focus, zotatifin is being evaluated as a
potential host-directed anti-viral therapy in patients with mild to
moderate COVID-19 in collaboration with the University of
California, San Francisco, under a $5 million grant sponsored by
the Defense Advanced Research Projects Agency.
Contacts:
Investors:Stephanie CarringtonWestwicke, an ICR
Company646-277-1282Stephanie.Carrington@westwicke.com
Media:Heidi Chokeir, Ph.D.Canale
Communications619-203-5391heidi.chokeir@canalecomm.com
eFFECTOR Therapeutics (NASDAQ:EFTR)
Historical Stock Chart
From Aug 2024 to Sep 2024
eFFECTOR Therapeutics (NASDAQ:EFTR)
Historical Stock Chart
From Sep 2023 to Sep 2024